Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.22% | -29.25% | 9.94% | -26.34% | 1.06% |
| Total Depreciation and Amortization | 13.72% | 19.14% | -14.68% | 44.18% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.09% | 29.97% | 55.51% | 100.75% | -59.15% |
| Change in Net Operating Assets | 215.27% | -108.62% | -224.39% | 112.00% | -66.60% |
| Cash from Operations | 45.80% | -38.52% | -0.52% | 41.39% | -32.40% |
| Capital Expenditure | 63.66% | 1.66% | -281.49% | -4.73% | -291.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 63.66% | 1.66% | -285.84% | -3.55% | -338.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -1.90% |
| Issuance of Common Stock | 30,716.47% | -44.22% | -98.65% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 30,716.47% | -44.22% | -98.65% | 789.61% | -1.90% |
| Foreign Exchange rate Adjustments | -124.84% | 478.74% | 107.49% | -812.97% | 144.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 999.90% | -36.17% | -123.10% | 266.77% | -16.38% |